Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2020

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2020



latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor - Pipeline Review, H1 2020, provides an overview of the Gastrointestinal Stromal Tumor (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 18, 18, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Gastrointestinal Stromal Tumor (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastrointestinal Stromal Tumor (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (Oncology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Gastrointestinal Stromal Tumor - Overview
Gastrointestinal Stromal Tumor - Therapeutics Development
Gastrointestinal Stromal Tumor - Therapeutics Assessment
Gastrointestinal Stromal Tumor - Companies Involved in Therapeutics Development
Gastrointestinal Stromal Tumor - Drug Profiles
Gastrointestinal Stromal Tumor - Dormant Projects
Gastrointestinal Stromal Tumor - Discontinued Products
Gastrointestinal Stromal Tumor - Product Development Milestones
Appendix

List Of Tables


Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by ABL Bio Inc, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories LLC, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals Inc, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ascentage Pharma Group International, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Bayer AG, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corp, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences Inc, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by CStone Pharmaceuticals Co Ltd, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals Inc, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Eisai Co Ltd, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Eli Lilly and Co, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Esperas Pharma Inc, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Exelixis Inc, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2020
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2020

List Of Figures


Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

Peritonitis (Gastrointestinal) - Drugs in Development, 2021

Peritonitis (Gastrointestinal) - Drugs in Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Peritonitis - Drugs In Development, 2021, provides an overview of the Peritonitis (Gastrointestinal) pipeline

USD 2000 View Report

Irritable Bowel Syndrome (Gastrointestinal) - Drugs in Development, 2021

Irritable Bowel Syndrome (Gastrointestinal) - Drugs in Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Drugs In Development, 2021, provides an overview of

USD 2000 View Report

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2019

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2019, provides an overview of the Gastrointestinal

USD 2000 View Report

Gastrointestinal Stromal Tumor (GIST) - Market Insight, Epidemiology and Market Forecast - 2028

Gastrointestinal Stromal Tumor (GIST) - Market Insight, Epidemiology and Market Forecast - 2028 report provides a detailed analysis of the Gastrointestinal Stromal Tumor (GIST) epidemiology and market

USD 6250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available